Literature DB >> 6686530

Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy.

F Loogen, H Kuhn, F Gietzen, B Lösse, H D Schulte, W Bircks.   

Abstract

In a total of 339 patients with hypertrophic cardiomyopathies (typical HOCM, n = 224; atypical HOCM, n = 30; HNCM, n = 80) the clinical course, the Sokolow-Lyon index in the ECG and the prognosis as demonstrated by cumulative survival rates were analysed to get more differentiated information for the characterization of these myocardial disorders. No change in the type of hypertrophic cardiomyopathy was found, indicating different clinical entities. No increase of the Sokolow-Lyon index was observed during follow-up. Only a small proportion of patients seemed to benefit from treatment with propranolol. Surgical treatment appears to be the therapy of choice, at least in the advanced stage of the disease refractory to medical treatment. In addition, strong evidence was obtained that surgical treatment improved the prognosis in patients with typical HOCM.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6686530     DOI: 10.1093/eurheartj/4.suppl_f.145

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

1.  Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; J R Gimeno; R Thaman; J Shah; D Ward; S Dickie; M T Tome Esteban; W J McKenna
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

2.  Natural history of hypertrophic cardiomyopathy.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 3.  The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

4.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

5.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

6.  DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience.

Authors:  A K Slade; N Sadoul; L Shapiro; L Chojnowska; J P Simon; R C Saumarez; B Dodinot; A J Camm; W J McKenna; E Aliot
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

7.  Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.

Authors:  F Cecchi; I Olivotto; A Montereggi; G Squillatini; A Dolara; B J Maron
Journal:  Heart       Date:  1998-04       Impact factor: 5.994

8.  Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.

Authors:  L Obergassel; T Lawrenz; F H Gietzen; F Lieder; C Leuner; H Kuhn; C Stellbrink
Journal:  Clin Res Cardiol       Date:  2006-03-21       Impact factor: 6.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.